“There’s little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs … More
The Federal Trade Commission and U.S. Department of Justice recently kicked off a series of listening sessions to examine barriers to competition in the drug industry.
The title of the first session—”Anticompetitive Conduct by Pharmaceutical Companies”—made it seem that regulators would chiefly investigate biotech firms. Yet by the…
Continue Reading
News Source: www.forbes.com
Leave a Reply